June 24, 2021
1 min watch
Save
VIDEO: Improving treatment options for patients with EGFR NSCLC
In this video, Nathan A. Pennell, MD, PhD, discusses a presentation from the virtual ASCO Annual Meeting in which researchers investigated the safety and efficacy of patritumab deruxtecan.
According to the abstract, the treatment was studied among patients with EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer.
“This is an exciting area of need for our patients,” Pennell, medical oncologist at the Cleveland Clinic and associate professor medical oncology at the Cleveland Clinic Lerner College, said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview; Janne P, et al. Abstract 9007. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Disclosures:
Disclosure: Pennell reports serving in a consulting or advisory role for Bristol Myer Squibb, Genentech and Janssen.
Read more about